Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Sells 10,580 Shares of Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 10,580 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $3.33, for a total transaction of $35,231.40. Following the sale, the insider owned 70,805 shares of the company’s stock, valued at $235,780.65. This trade represents a 13.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total transaction of $65,229.12.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total transaction of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt acquired 7,851 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.54 per share, with a total value of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

Shares of NASDAQ SHPH opened at $3.28 on Friday. Shuttle Pharmaceuticals Holdings, Inc. has a fifty-two week low of $2.90 and a fifty-two week high of $55.90. The stock has a market cap of $2.09 million, a price-to-earnings ratio of -0.07 and a beta of 0.29. The firm’s 50-day simple moving average is $5.15 and its 200 day simple moving average is $10.18.

Analysts Set New Price Targets

SHPH has been the topic of a number of recent research reports. Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen upgraded Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Shuttle Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Connective Capital Management LLC purchased a new position in shares of Shuttle Pharmaceuticals in the 3rd quarter worth approximately $357,000. Ikarian Capital LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter valued at approximately $124,000. Boothbay Fund Management LLC purchased a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter valued at approximately $37,000. Finally, Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the fourth quarter worth $26,000. Institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .